Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

CompletedOBSERVATIONAL
Enrollment

198

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

February 8, 2023

Study Completion Date

February 8, 2023

Conditions
Rheumatoid Arthritis
Trial Locations (18)

11525

251 Air Force Hospital of Athens, Athens

12462

"University General Hospital of Athens Attikon", Athens

26500

University General Hospital of Patras, Pátrai

41110

Univerisity General Hospital of Larisa, Larissa

45500

University General Hospital of Ioannina, Ioannina

Unknown

General Hospital of Athens Gennimatas, Athens

Ippokrateio General Hospital of Athens, Athens

Laiko General Hospital of Athens, Athens

Naval Hospital of Athens, Athens

Nearchou 18, Crete

Univerisity General Hospital of Heraklion, Heraklion

KAT General Hospital of Attica, Kfisia

Univerisity General Hospital of Larisa, Larissa

Agios Andreas General Hospital of Patra, Pátrai

Euromedica General Clinic of Thessaloniki, Thessaloniki

Euromedica Kyanous Stavros General Clinic, Thessaloniki

General Hospital of Thessaloniki Ippokrateio, Thessaloniki

Asklipieio General Hospital of Voula, Voula

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04079920 - Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter